Horstem is the world's first drug based on equine umbilical cord mesenchymal stem cells authorised by centralised registry by the European Medicines Agency.

HorStem is an injectable suspension indicated for the lameness reduction associated with mild to moderate degenerative joint disease in horses.

HorStem has 15 million Equine Umbilical Cord Stem Cells as an active principle.

It has been specially developed in a “ready to use” format that allows its easy and safe injection under field conditions without the need for handling and / or thawing by the veterinarian. It is a veterinary prescription medicine.

*High resistance pierceable vial that ensures the sterility, viability and quality of the product at all times.

Pluripotent Mesenchymal Cells
Regenerative medicine without systemic adverse effects
Long-term clinical effect
No doping
Quality, safety and efficacy guaranteed by the EU
Ready to use product

Clinical results

Clinical trials designed and conducted by our scientific team have shown that HorStem is effective in reducing lameness in horses with mild to moderate degenerative joint disease.

All of our clinical trials have been carried out following the international standards for the homogenisation of clinical trials VICH GL9 and after authorisation from the Spanish Agency of Medicines and Health Products (AEMPS).

72% of the treated horses reduced their degree of lameness to absence of lameness or inconsistent lameness

(≤grade 1 according to the American Association of Equine Practitioners).

Likewise, long-term studies have shown that the efficacy of HorStem is very long-term, showing that 83% of the animals did not relapse in their symptoms or need additional medication 12 months after the application of HorStem.

Horstem - Lameness reduction chart